Related Experiment Videos
[Biphenotypic acute leukemia. Clinical, morphological, cytochemical and immunophenotypic studies]
Zhonghua Nei Ke Za Zhi
|November 1, 1991
Summary
Two acute leukemia patients showed mixed lymphoid and myeloid markers, indicating biphenotypic acute leukemia. This finding impacts diagnosis and treatment strategies for mixed acute leukemia.
Area of Science:
- Hematology
- Immunophenotyping
- Cancer Biology
Background:
- Acute myeloid leukemia (AML) classification relies on morphology and immunophenotype.
- Biphenotypic acute leukemia presents diagnostic challenges due to co-expression of myeloid and lymphoid markers.
Observation:
- Two AML cases classified as M1 by the French-American-British (FAB) criteria exhibited lymphoid markers (SmIgG, CD19, CD20, DR, PAS in case 1; CD9, CD10, DR, PAS in case 2).
- Both cases also expressed the CD38 antigen on blast cells.
Findings:
- The immunophenotype and cytochemistry data align with criteria for biphenotypic acute leukemia.
- This suggests a complex cellular origin or aberrant differentiation in these leukemic blasts.
Implications:
- Accurate diagnosis of biphenotypic acute leukemia is crucial for appropriate treatment selection.
- Understanding the immunophenotypic profile aids in predicting treatment response and patient prognosis.
- Further research into the pathogenesis of mixed acute leukemias is warranted.